Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:AGTC

Applied Genetic Technologies (AGTC) Stock Price, News & Analysis

Applied Genetic Technologies logo

About Applied Genetic Technologies Stock (NASDAQ:AGTC)

Key Stats

Today's Range
$0.39
$0.39
50-Day Range
$0.37
$0.42
52-Week Range
$0.23
$2.83
Volume
N/A
Average Volume
943,490 shs
Market Capitalization
$26.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.

Receive AGTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Applied Genetic Technologies and its competitors with MarketBeat's FREE daily newsletter.

AGTC Stock News Headlines

Do this to position yourself after last month’s tech’s tumble…
A lot of investors saw a significant portion of their portfolio erased after $1.7 trillion was wiped out of the Magnificent 7… Now they’re scratching their heads trying to figure out where to invest their money going forward. Well, you won’t need to search for long because the pullback from mega-cap tech is allowing other sectors and smaller companies to stand out… Setting up what could be a massive once-in-a-lifetime “double dip” opportunity on an often overlooked class of stocks. I’m talking about small cap stocks that pay dividends every month…
Genetic Technologies Limited (GENE)
See More Headlines

AGTC Stock Analysis - Frequently Asked Questions

Applied Genetic Technologies Co. (NASDAQ:AGTC) issued its quarterly earnings data on Tuesday, November, 9th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by $0.05.

Based on aggregate information from My MarketBeat watchlists, some other companies that Applied Genetic Technologies investors own include Tesla (TSLA), Meta Platforms (META), NIO (NIO), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD) and Viking Therapeutics (VKTX).

Company Calendar

Last Earnings
11/09/2021
Today
1/09/2025
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:AGTC
Fax
N/A
Employees
83
Year Founded
N/A

Profitability

Net Income
$-68,940,000.00
Pretax Margin
-21,537.54%

Debt

Sales & Book Value

Annual Sales
$320,000.00
Book Value
$0.26 per share

Miscellaneous

Free Float
64,859,000
Market Cap
$26.62 million
Optionable
Optionable
Beta
1.55

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

This page (NASDAQ:AGTC) was last updated on 1/9/2025 by MarketBeat.com Staff
From Our Partners